GPCR therapeutic monoclonal antibodies

GPCR therapeutic monoclonal antibodies · 25. January 2024

CCR8 Targeting: A Promising Strategy for Cancer Immunotherapy and Beyond

SYnAbs has developed therapeutic monoclonal antibodies to CCR8 biomarker to deplete Treg and block the internalization of CCL1-CCR8 as immunotherapy for oncology diseases

GPCR therapeutic monoclonal antibodies · 20. September 2022

SYnAbs signs a research agreement with Domain Therapeutics to discover therapeutic antibodies on GPCRs

SYnAbs and Domain Therapeutics enter into a strategic partnership for the discovery and development of therapeutic antibodies targeting complex G Protein Coupled Receptor targets for immuno-oncology indications

GPCR therapeutic monoclonal antibodies · 13. August 2022

G protein-coupled endothelin receptors and their natural and therapeutic ligands

From the discovery of an unique peptide ligand to the clinical relevance of ETA and ETB receptors and the current therapeutic pipeline of small molecules and monoclonal antibodies targeting these GPCR transmembrane proteins

GPCR therapeutic monoclonal antibodies · 30. April 2022

Therapeutic trends of G protein-coupled receptor drugs as Antibody Drug Conjugates candidates

SYnAbs can help you develop therapeutic antibody-drug conjugates by specifically targeting transmembrane proteins using innovative proprietary technologies.

GPCR therapeutic monoclonal antibodies · 05. April 2022

CX3CR1, GPCR CX3C chemokine receptor 1 (CX3CR1): transmembrane receptor of therapeutic interest?

SYnAbs discovers antibodies to transmembrane proteins including GPCR chemokine receptors thanks to unique cell immunization technology and expertise

GPCR therapeutic monoclonal antibodies · 19. March 2022

Immuno-Oncology Therapeutic Potential of Adenosine Receptors: Targeting the Purinergic Pathway

SYnAbs develops therapeutic monoclonal antibodies with agonistic or antagonistic effects to highly homologous G Protein-Coupled Receptors transmembrane proteins

GPCR therapeutic monoclonal antibodies · 11. September 2021

C3a and C5a anaphylatoxin receptors, therapeutic GPCR targets of the complement system

SYnAbs are unique therapeutic effector monoclonal antibodies targeting anaphylatoxin C3aR GPCR. First-in-class functional antibody targeting complex transmembrane proteins and G protein-coupled receptors.

GPCR therapeutic monoclonal antibodies · 30. August 2021

Therapeutic targets of the complement system

The Complement System and its druggable targets by antibodies: C3aR, C5aR GPCR membrane receptors, C3, C4, C5 ligands

GPCR therapeutic monoclonal antibodies · 14. August 2021

Orphan GPCR and their untapped therapeutic potential: the next wave of antibody drug targets?

Untapped therapeutic potential of orphan GPCR and SYnAbs functional monoclonals anti-GPCR. Generation of new antibody therapeutics targeting orphan membrane receptors.

GPCR therapeutic monoclonal antibodies · 30. June 2021

CC chemokine receptors: latest news on Beta chemokine receptor therapeutics

SYnabs generate therapeutic monoclonal antibodies against CC chemokine receptors thanks to DNA, cell immunization strategies, unique rat-LOU species and proprietary adjuvant